<DOC>
	<DOCNO>NCT02469246</DOCNO>
	<brief_summary>This study evaluate efficacy , safety , tolerability switch abacavir/lamivudine ( ABC/3TC ) emtricitabine/tenofovir alafenamide ( F/TAF ) versus maintain ABC/3TC HIV-1 infect adult virologically suppress regimen contain ABC/3TC .</brief_summary>
	<brief_title>Switch Study Evaluate F/TAF HIV-1 Infected Adults Who Are Virologically Suppressed Regimens Containing ABC/3TC</brief_title>
	<detailed_description />
	<mesh_term>Lamivudine</mesh_term>
	<mesh_term>Anti-Retroviral Agents</mesh_term>
	<criteria>Key The ability understand sign write informed consent form On antiretroviral regimen contain ABC/3TC FDC combination one third agent ≥ 6 consecutive month prior screen Plasma HIV1 RNA level &lt; 50 copies/mL ≥ 6 month precede screen visit ( measure least twice use assay ) without experience two consecutive HIV1 RNA detectable level achieve confirm ( two consecutive ) HIV1 RNA detectable level current regimen past year Plasma HIV1 RNA &lt; 50 copies/mL screen visit Normal ECG Estimated glomerular filtration rate ( GFR ) ≥ 50 mL/min accord Cockcroft Gault formula creatinine clearance Hepatic transaminase ( AST ALT ) ≤ 5 × upper limit normal ( ULN ) Total bilirubin ≤ 1.5 mg/dL , normal direct bilirubin Adequate hematologic function Serum amylase ≤ 5 × ULN Males females childbearing potential must agree utilize highly effective contraception method nonheterosexually active practice sexual abstinence screen throughout duration study treatment 30 day follow last dose study drug Key A new AIDSdefining condition diagnose within 30 day prior screen Hepatitis B surface antigen ( HBsAg ) positive Individuals experience decompensated cirrhosis Individuals receive ongoing treatment bisphosphonate treat bone disease ( eg , osteoporosis ) Pregnant lactate female Have implant defibrillator pacemaker Current alcohol substance use judge investigator potentially interfere study compliance A history malignancy within past 5 year ( prior screen ) ongoing malignancy cutaneous Kaposi 's sarcoma ( KS ) , basal cell carcinoma , resect , noninvasive cutaneous squamous carcinoma . Active , serious infection ( HIV1 infection ) require parenteral antibiotic antifungal therapy within 30 day prior Day 1 Visit Any clinical condition prior therapy , opinion investigator , would make individual unsuitable study unable comply dose requirement Participation clinical trial ( include observational trial ) without prior approval Medications exclude due potential interaction emtricitabine ( FTC ) , TAF , ABC 3TC Note : Other protocol define Inclusion/Exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>HIV</keyword>
	<keyword>HIV-1 Positive</keyword>
	<keyword>Virologically-Suppressed</keyword>
</DOC>